To: Stock
Exchange
Date: 3
April 2024
|
|
|
|
CT Private Equity Trust
PLC
LEI:
2138009FW98WZFCGRN66
Preliminary Announcement for the
Year Ended 31 December 2023
CT Private Equity Trust PLC today
announces its unaudited financial results for the year ended 31
December 2023.
Financial Highlights
·
Share price total return for the year of 17.6 per
cent for the Ordinary Shares.*
· NAV of
702.50 pence per Ordinary Share reflecting a total return for the
year of 2.8 per cent.*
· Total
quarterly dividends for the year of 27.98 pence per Ordinary
Share. Quarterly dividend of 7.01 pence per Ordinary Share to
be paid on 30 April 2024.
· Dividend yield of 6.0 per cent based on the year-end share
price.*
· 25-year anniversary - gain of 11.6 times the original
investment over the 25-year period. Significantly outperforming the
stock market for the same period (FTSE All-Share 2.4
times).
*see Alternative Performance
Measures
Chairman's Statement
Fellow Shareholders,
This report is for the year ended 31
December 2023. The NAV per share at the year-end was 702.50p
(2022: 710.65p). Taking account of the dividends received by
Shareholders during this year your Company achieved a net asset
value ("NAV") total return of 2.8 per cent.
The share price at the year-end was
468.00p per share (2022: 423.00p). During the year the share
price discount narrowed from 40.5 per cent as at 31 December 2022
to 33.4 per cent as at 31 December 2023. As a consequence,
the share price total return for the year was an impressive 17.6
per cent. This compares to a total return from the FTSE
All-Share Index for 2023 of 7.9 per cent.
During the year the Company made new
investments, either through funds or as co-investments, totalling
£110.9 million. Realisations and associated income totalled £61.8
million. Outstanding undrawn commitments at the year-end were
£209.3 million of which £26.4 million was to funds where the
investment period had expired.
Approximately 86 per cent of the valuation by value is based on 31
December 2023 valuations and 14 per cent on
September 2023 valuations.
The Company's performance fee
arrangements contain a hurdle rate, calculated over rolling
three-year periods, of an IRR of 8.0 per cent per annum. The annual
IRR of the NAV for the three-year period ended 31 December 2023 was
17.8 per cent and, consequently, a performance fee of £4.8 million
is payable to the Manager, in respect of 2023. This is the eleventh
consecutive year that a performance fee has been payable,
demonstrating consistent performance and providing Shareholders
with an attractive total return, which includes capital growth and
an above average dividend yield.
Dividends
Since 2012 your Company has paid a
substantial dividend from realised profits allowing Shareholders to
participate, to some degree, directly in the proceeds of the steady
stream of private equity realisations which the Company achieves.
This policy is well received by Shareholders and provides for a
steadily growing dividend with downside protection. Your Board is
fully committed to maintaining this general approach for the
foreseeable future.
The Company's quarterly dividends
are payable in respect of the quarters ended 31 March, 30 June, 30
September and 31 December and are paid in the following July,
October, January and April respectively. As Shareholders do not
have an opportunity to approve a final dividend at each Annual
General Meeting, Shareholders are asked to approve the Company's
dividend policy at the forthcoming Annual General
Meeting.
In accordance with the Company's
stated dividend policy, the Board recommends a further quarterly
dividend of 7.01 pence per Ordinary Share, payable on 30 April 2024
to Shareholders on the register on 12 April 2024 and an ex-dividend
date of 11 April 2024. Total dividends paid for the year therefore
amount to 27.98 pence per Ordinary Share equivalent to a dividend
yield of 6.0 per cent at the year-end.
Financing
To reflect the growth in the size of
the Company, following the year end, during February 2024, the
Company entered into a revised loan agreement with RBSI and State
Street.
The revised loan agreement increased
the €25 million term loan with RBSI to €60 million and retained the
revolving credit facility with RBSI and State Street at £95
million. The term of the agreement, which was due to expire
in June 2024, was extended to February 2027.
The Board is pleased to have secured
this larger facility which allows the Company to maintain a
moderately but flexibly geared structure with the ability to draw
borrowings in multiple currencies.
Share Buybacks
At the Annual General Meeting
("AGM") held on 23 May 2023, the Board sought and received from
Shareholders the authority to buyback up to 14.99% of the Company's
share capital. Buybacks can only be made at a cost which is below
the prevailing net asset value and, in the opinion of Directors,
would be in the interests of Shareholders as a whole.
During December 2023 the Company
bought back 92,000 of its ordinary shares to be held in treasury.
The discount at which these shares were bought back was 33%.
This was in addition to 1,096,491 shares bought back during
2022.
These shares are held in treasury to
allow the Company to re-issue them quickly and cost effectively. At
last year's AGM the Board sought and received the authority from
Shareholders to re-issue treasury shares or issue new shares,
subject to limitations on the number and price. Treasury shares can
only be re-issued and new shares issued at a price which would not
dilute the NAV of existing Shareholders.
The Board seeks renewal of these
buyback and reissuance authorities at the AGM to be held on 29 May
2024.
Directorate Change
The Board recognises the value in
both attracting fresh talent and the maintenance of continuity and
accordingly a plan has been developed to ensure an orderly
succession as Directors retire.
As part of this plan, David Shaw
retired from the Board at the conclusion of the Company's Annual
General Meeting held on 23 May 2023.
Following a thorough selection
process, which included the services of a search company, Craig
Armour was appointed to the Board with effect from 19 December
2023.
Until 2021 Craig was an investment
partner at Edinburgh Partners where his roles included head of
European portfolios and the manager of The European Investment
Trust PLC. Previously, he was a senior investment director at
Lloyds Development Capital, a partner at Penta Capital, and a
corporate financier at Noble Grossart. Craig is a member of the
Institute of Chartered Accountants of Scotland.
As a further part of this plan,
Elizabeth Kennedy will retire from the Board at the conclusion of
the Company's 2024 Annual General Meeting to be held on 29 May
2024.
Elizabeth has served as a Director
since July 2007 and since 2009 she has Chaired the Company's Audit
Committee with great diligence and commitment. I wish to
place on record the Board's appreciation for her support and
guidance throughout her tenure and to thank Elizabeth for her
significant contribution to the Company's success.
Following her retirement, Craig
Armour will be appointed Chair of the Audit Committee.
Annual General Meeting
The Annual General Meeting ("AGM")
will be held at 12 noon on 29 May 2024 at the offices of Columbia
Threadneedle Investments, Cannon Place, Cannon Street, London EC4N
6AG. This will be followed by a presentation by Hamish Mair, the
Company's Investment Manager on the Company and its investment
portfolio.
For Shareholders who are unable to
attend the meeting, any questions they may have regarding the
resolutions proposed at the AGM or the performance of the Company
can be directed to a dedicated email account,
petagm@columbiathreadneedle.com, by Wednesday 22 May 2024. The
Board will endeavour to ensure that questions received by such date
will be addressed at the meeting. The meeting will be
recorded and will be available to view on the Company's website,
ctprivateequitytrust.com, shortly
thereafter. All Shareholders that cannot attend in person are
encouraged to complete and submit their Form of Proxy or Form of
Direction in advance of the meeting to ensure that their votes will
count.
25
Year Anniversary
Your Company was established on 22
March 1999 and so has just passed its 25th Anniversary.
The returns to shareholders over that period, described in detail
in the Investment Manager's review, have been excellent, far
outpacing the stock market in general. These prove the case for
long term investment in private equity and I would like to thank
our shareholders for their patient support and commitment. It is
notable and commendable that the management of the Company has been
constant over the first quarter century.
Review and Outlook
As expected 2023 has turned out to
be a year of adjustment. Despite this the Company's portfolio has
proved resilient and we delivered a positive total return in NAV
and good growth in dividends The economic challenges which are
presented by higher inflation and interest rates were anticipated
in last year's report and this has clearly affected the investment
environment for private equity internationally. As described
in the Investment Manager's review your company's portfolio has
coped well with these challenges. This is based on strong
underlying fundamentals for our investee companies which have
recorded impressive growth in revenues and profits over the year,
tempered by a slight softening in valuation multiples.
The strong flow of exits which has
characterised recent years has moderated significantly. Given
that our exits are on average achieved at a significant premium to
recent carrying value, it is no surprise that our NAV has made
relatively modest progress compared to years when realisations were
much higher.
The slowdown in realisations flows
from the macroeconomic situation. The increase in interest rates,
which is accompanied by a noticeable tightening of the credit
markets, results in one of the key elements of management buy-outs
- i.e. debt - becoming more difficult to arrange with a consequent
slow down in deal-making. Although the stock of private equity
committed capital remains very healthy, it usually requires to be
deployed alongside a similar or greater quantum of debt. This
equity remains available and 'in the system' and will be deployed
steadily over the coming years as debt availability
improves.
Whilst investors' long term
enthusiasm for private equity remains intact, fresh commitments to
private equity funds have decreased in most markets this year. This
is in part due to the 'denominator effect' where substantial
deployments in recent years now represent larger than expected
components of overall portfolios which have not grown as quickly as
projected. This is currently being corrected via a reduction or
hiatus of new commitments to private equity until equilibrium is
regained.
This moderation in activity
resulting from higher priced and scarcer debt, reduced fresh equity
commitments and more caution in general, is not without benefits
for your Company. The flow of investment opportunities that your
managers appraise remains very strong reflecting the breadth of the
mid-market universe we address and the depth of our networks in
these markets internationally. As we look forward into 2024 the
combination of our steadily maturing portfolio and our newly
extended and enlarged borrowing capacity leaves your Company in
good stead to deliver further gains to shareholders whilst laying
the foundations for future growth.
Richard Gray
Chairman
Investment Manager's Review
Introduction
The principal feature of 2023 has
been a slowdown in activity in private equity markets
internationally. This comes after a number of very strong and
active years and therefore a year of adjustment is not unexpected.
The most obvious manifestation of this has been in a decrease in
realisations by just over 50% compared with last year, which was a
strong, but not record breaking year, for exits. The reasons for
this are not difficult to understand, with inflation at the highest
level for decades, interest rates having risen sharply and most of
the major economies in which we invest experiencing sluggish growth
or mild recession. Private Equity as we have often emphasised is a
resilient asset class with a unique mode of investment with
alignment, incentivisation and active involvement as its hallmarks.
This means that growth can be achieved even when the economic
background is challenging, especially where we are investing in
companies in niche sectors with secular growth in their end
markets. However, private equity-backed companies are not
completely immune from the pressures brought about by a challenging
macro-economic background. Your portfolio made progress this year
despite these pressures. The portfolio is very well diversified and
as we have often noted this is a deliberate policy designed to
reduce risk and provide protection and growth under a wide range of
circumstances.
New Investments
There have been many investment
opportunities presented to us this year. We are highly selective
backing both those managers which have already delivered for us and
carefully choosing new managers with the necessary skills and track
record to succeed. Our new investments this year cover both
categories.
We have committed to twelve new
private equity funds this year. These are diverse by manager and
geography. They have different investment styles and sector
preferences; but they are all mid-market funds. We maintain our
belief that investing in the mid-market of the UK and Europe, and
selectively in North America, allows us and our investment partners
to buy companies in an innately inefficient market which offers
superior returns compared with buying larger, better known
companies which are usually offered in heavily intermediated
processes.
In the UK, we committed £8 million
to Kester Capital III a UK focussed lower mid-market buyout manager
which we have backed before in two previous funds and in several
co-investments.
We also committed £8 million to
Axiom I, a debut mid-market enterprise software fund, where we know
the principals from earlier in their careers.
We committed €5 million to Magnesium
Capital I, a European
energy transition fund, led by an emerging manager with which we
have co-invested before.
We have backed funds with a European
or global focus.
€5 million has been committed to Hg
Mercury 4, a lower mid-market software and services fund investing
in Europe and North America. This is the second Hg-managed fund to
which we have committed.
£10 million was committed to
Inflexion Partnership Capital III, the latest in the series of
funds from this key relationship. The latest fund is focussed on
European mid-market minority investments. The Company has backed
the first two iterations of this fund series which are performing
strongly.
We have reinforced our exposure to
European country or regional funds.
€8 million has been committed to
Wise Equity VI, the latest fund by one of the leading Italian
mid-market buyout managers. We have invested in previous Wise
Equity-managed funds as secondary investors from other managed
funds.
€10 million has been committed to
Montefiore Expansion Fund following our previous commitments to
Montefiore Fund IV and Fund V. The manager, Montefiore, has elected
to split its fund series in two and the Company has elected to
invest in the lower mid-market fund, which will make investments in
companies with enterprise value of between €25 million and €100
million in the service sector mainly in France.
€4.0 million was committed to Aurica
IV, a Spanish lower mid-market growth equity fund. We have been
tracking Aurica for several years following its spin-out to become
an independent firm.
€2.7 million has been committed to
KKA Fund II, the lower mid-market German emerging
manager.
In North America we have made three
new commitments.
$8 million has been committed to
MidOcean VI, a US mid-market buyout fund whom we have backed
through one of our other funds before.
CAD 10 million has been committed to
Torquest VI, one of the leading Canadian mid-market buyout
funds.
$10 million was committed in total
to Level 5 Fund II ($5 million) and Purpose Brands ($5 million), a
US consumer franchise fund and co-investment fund, based in
Atlanta, Georgia. The funds are managed by US-based Level 5 Capital
Partners, an emerging manager focussed on consumer franchise
businesses.
The funds element of the portfolio
has been active throughout the year making new
investments.
In the UK, SEP VI called £1.1
million for its first two investments; Cresset, the software
business focussed on the design of small molecules for drug
discovery, and Pelion, an internet of things connectivity
business.
Kester Capital called £0.7 million
for MAP Patient, the leader in market access consulting services to
the pharmaceutical and biotech sectors aiming to accelerate patient
access to ground-breaking medicines, devices and
diagnostics.
In different sectors, Piper Equity
called £0.6 million from its Fund VII for jewellery company Monica
Vinader, as it continues with this investment having previously
invested from Fund VI. Piper VII also called £0.5 million for
tourist excursion company Rabbie's Trail Burners and £0.6 million
for investment in Ancient & Brave, a natural supplements and
wellness company.
Inflexion VI called £0.7 million for
a follow-on investment in K2 the IT recruitment specialist, which
acquired a US company which focuses on enterprise integrations. It
also called £0.7 million for Steripack, the contract manufacturing
services provider for medical devices.
Magnesium Capital I (the UK-based
manager, pan-European fund) called £1.7 million immediately
following closing to invest in Embriq, the software and IT managed
services provider for utilities and data intensive industries. A
further £0.6 million was called for SCADA, the software and control
systems provider for renewables energy plants, and £0.4 million for
Inopower, the provider of e-boilers used in district and industrial
heating.
Apposite Healthcare III called £1.2
million for various follow-ons, the largest being £0.8 million in
Riverdale, the UK dentistry provider.
Hg Saturn 3 drew £1.5 million for
Access, the provider of enterprise resource planning software and
£1.1 million across the year for IFS/Workwave, the provider of
field service management software.
In Germany, DBAG VIII called £0.5
million for Metalworks which designs and manufactures high quality
fashion accessories such as belt buckles, fasteners and studs for
luxury fashion brands.
France-based Montefiore V called
£1.5 million throughout the year for eleven companies in its
portfolio. The largest amounts were £0.4 million for Generix, the
industrial software provider, and £0.3 million for additional
investment in CCGM, a group of oncology clinics mainly focussed on
radiotherapy treatment.
Volpi III called £2.0 million mainly
for investment in Cyclomedia, the Netherlands-based geospatial data
company, in which we are also a co-investor.
There was notable activity in the
Nordic region with Summa III calling £0.5 million for Velsera,
which is the combination of three health-tech companies focussed on
healthcare data analytics. Procuritas VII called £1.8 million for
Werksta, We Select and Nordic Biomarker. £1.0 million was for
Werksta, the automotive repair shop chain which the Company
previously had exposure to in Procuritas Fund V. We Select is a
digital recruitment firm which integrates social media to its
platform and Nordic Biomarker produces advanced reagents for IVD
coagulation analysers which tests blood for abnormalities.
Nordic-based Verdane XI called £0.9 million for Apoteka, Fashion
Cloud, Urban Sports Club and Ebertlang. The largest amounts were
for Apoteka, a fulfilment provider to the largest online pharmacy
in Denmark and Fashion Cloud, a B2B software company for the
apparel and footwear industry.
Spanish fund Corpfin V called £1.3
million to fund three investments, including £0.3 million for
residential property management business Mediterráneo, £0.3 million
for roadside assistance company Gruas Fuentes and £0.6 million for
the English language school for children Kids&Us. All
investments had been funded by the fund's bridging facility at
closing earlier in 2023. The Company had previously been an
investor in Kids&Us through Corpfin Fund IV.
In the US, Level 5 Capital Partners
II & Purpose Brands drew £4.6 million across both funds for
four investments, KidStrong, Restore, GoDog and 2U Laundry. The
fund had invested in these following the first close and we
invested via the second close, giving us full visibility into the
performance of the assets thus far. Level 5 concentrates on
consumer-focussed franchise growth investments.
US financial services and technology
focused fund Corsair Capital VI called £2.2 million for HungerRush.
HungerRush is the all in one point of sale and restaurant
management platform.
Lastly, US-based Mid Ocean VI called
£0.5 million for Smith Systems, a leading B2B workplace safety
training platform which amongst other activities provides driver
safety training for commercial fleets.
We have added no fewer than 10
co-investments to the portfolio during 2023.
We have invested $2.4 million in the
MVM-led life sciences company GT Medical. This company has
developed an innovative brain cancer treatment consisting of
bioresorbable tiles with embedded radioactive caesium seeds. This
is thought to extend life and promote recovery.
We have also invested £4.1 million
(80% of our expected investment in the business) in LeadVenture, a
leading SaaS provider of digital retailing, digital storefronts,
e-commerce, proprietary data and vertical ERP dealer management
software. The company's customers are in the non-auto sector such
as RVs, agriculture machinery and transportation. The lead for the
investment is San Francisco-based True Wind Capital.
£2.7 million has been invested (£5.0
million commitment) in Cardo, a Wales based provider of repair,
maintenance and upgrading services mainly to the social housing
sector. Much of the impetus comes from the transition of this
housing stock to become more energy efficient and sustainable. The
deal is led by Buckthorn, with which we have co-invested with
several times and who specialise in energy transition
investments.
£3.6 million has been invested
alongside August Equity in StarTraq, a provider of software to
police forces and local authorities allowing them to efficiently
issue and process speeding tickets. The technology has an
increasing range of applications with, for example, the capability
of capturing accurately on camera drivers who are using handheld
mobile phones whilst driving. The company also has a large untapped
market opportunity internationally where it already has a small
foothold.
In addition, we have also invested
£1.2 million alongside August Equity in OneTouch, a market leading
software provider serving the social care market. This software
allows carers to meet client requirements more efficiently and the
care companies themselves to manage their staff productively in
what is a closely regulated sector.
€8.4 million has been invested in
the Volpi led co-investment in Cyclomedia. Volpi has been invested
in this Netherlands headquartered provider of intelligent
street-level geospatial data and information solutions company
since 2018 and we are increasing our exposure to this high
performing asset. Cyclomedia's client base includes local
municipalities who require comprehensive, accessible and digitally
formatted information on properties within their areas, mainly for
the purposes of local taxation and rates. From its Northern
European base, the company has begun a process of expansion
internationally and Volpi believe that there is considerable
further growth to be achieved.
$8.0 million has been invested in
Asbury Carbons, a US-based producer of milled graphite products
with a diverse range of industrial applications. The investment is
led by New York-based Mill Rock Capital and Asbury is an intriguing
opportunity to revitalise a long-established company with
operational improvements and product extensions.
€5.2 million has been invested in
Braincube, an Industrial Internet-of-Things ("IIoT") software
company based in France which provides software solutions primarily
for continuous manufacturing processes. The lead on the investment
is our longstanding partner SEP.
€6.0 million has been invested in
Utimaco, a Germany-based company providing mission-critical
professional cybersecurity and data intelligence solutions for
critical infrastructures.
€3.1 million was invested (€4.0
million committed) to co-investment Educa Edtech, a Spanish
e-learning business which provides self-paced courses including
master's degrees. The business is international with a major
presence in Spanish speaking countries. The company has an
unrivalled portfolio of course content in an accessible online
format and is expected to benefit from the growth in the e-learning
market which is around 14% per annum. The deal is led by Aurica and
is to some extent a 'stapled' deal which we have access to by
virtue of our commitment to the fund, noted above.
Realisations
Notwithstanding the slowdown, there
have been many realisations across the portfolio.
We have completed the sell down of
energy services company Ashtead Technology, which is now listed,
with £12.9 million realised during the year. This brings total
proceeds to £19.9 million representing 2.5x cost and an IRR of 19%.
This investment was led by Buckthorn with which we have three other
co-investments.
Kester Capital II returned £2.7
million (4.8x, 60% IRR) from the sale of Vixio, the leader in the
provision of regulator and compliance intelligence to the payments
market. Kester Capital also returned £1.0 million from the
redemption of loan notes in insurance company ATEC, which is
performing strongly.
Our longstanding partner Inflexion
has had a series of exits across its range of funds. £1.6 million
was returned from travel company Scott Dunn where the holding
period coincided with a crisis for the industry due to the pandemic
(1.4x, 4% IRR). £1.1 million came in from the sale of software
services company Mobica, where Inflexion's Partnership Capital Fund
I made an excellent return (5.6x, 29% IRR). £0.7 million was
returned from international foreign exchange specialist Global
Reach Group (3.1x, 19% IRR). Inflexion also exited the social media
and influencer marketing agency Goat returning £0.4 million (3.9x,
78% IRR). Other notable exits include the sale by Inflexion 2012
Co-investment Fund of the specialist design engineering services
company PDMS which sells to the oil and gas sector, returning £0.7
million. Inflexion also sold Chambers, the legal directory and
rankings business, and returned a combined £1.1m (4.7x cost and 31%
IRR) from their buyout funds IV and V.
As noted above Piper exited
jewellery company Monica Vinader returning £0.4 million in a sale
to Bridgepoint (2.1x, 11% IRR). Piper have continued in the
investment alongside Bridgepoint in Piper VII.
Volpi have sold Medinet, the
insourced solutions provider to the healthcare sector, returning
£1.7 million (3.2x cost, 18% IRR).
We have received the final tranche
from the sale of the RJD led investment in apprenticeship and
training company Babington, which was £0.7 million, bringing the
final return to 0.9x cost.
The Agilitas 2015 Fund has had a
good exit with the sale of Hydro International, the water services
company to CRH plc. This realised £2.1 million representing 3.1x
cost.
The flow of realisations has
continued in continental Europe.
In Spain, Corpfin IV returned £2.5
million from the sale of care company Grupo 5 (6.1x, 51% IRR) and
£3.7 million for Kids&Us (5.4x, 50%), the English language
school for children. Corpfin re-invested in Kids&Us from a
later fund, and we therefore have maintained an exposure to this
company.
There have been a number of exits
from our French-managed funds. Chequers XVI exited Paris-based
landfill site operator Environnement Conseil Travaux (ECT)
returning £0.8 million and Italy-based Bozzetto, the provider of
speciality chemicals for the textiles industry, returning £0.5
million (4.3x cost, 28% IRR). Chequers XVII sold premium zips
business Riri returning £1.2 million (2.4x, 34% IRR) and Italian
HVAC equipment provider MTA, returning £0.7 million (3.2x cost, 40%
IRR). Also in France, Ciclad 4 exited wine drums company H&A
Location returning £0.7 million with an excellent return of c.8x
cost. Ciclad 5 has sold specialist vehicle axle manufacturer
Paillard (1.8x cost, 10% IRR) and has refinanced Edeis (engineering
project management) returning an aggregate £0.7 million. ArchiMed
II returned £1.0 million principally from the sale of gene therapy
company Polyplus. This represented 4.6x cost and an IRR of
75%.
In Germany, DBAG's various funds
have achieved several exits. £0.4 million came in from speciality
chemicals producer Heytex (1.2x cost). £1.0 million was returned
from Italian company Pmflex, a leading European manufacturer of
electrical installation conduits (2.3x, 65% IRR). DBAG also sold
prison phone communications company Telio returning £0.5 million.
DBAG VII also sold Cloudflight, the IT services provider focussed
on digitalisation and cloud-based transformation, returning £1.1
million (4.4x cost, 52% IRR).
In Central Europe, ARX exited
electro-mechanical engineering company TES in the sale to a
consortium including Avallon noted above. This returned £1.2
million (2.7x, 40% IRR).
In Finland, workplace booth company
Framery is staging a strong post-COVID recovery and has been
refinanced returning £0.3 million. Summa II, the Nordic sustainable
fund returned £0.5 million from the sale of construction sector
software company Infobric which returned 3.8x cost and an IRR of
36%. Summa I exited Kiona, the building control system software for
energy optimisation, returning £0.4 million (1.8x, 12% IRR) as well
as selling Norsk Gjenvinning via a continuation vehicle returning
£0.3 million (2.1x cost, 14% IRR).
£1.2 million was returned from the
Italian Portfolio, which was acquired as a secondary some years
ago, with Progressio II exiting Garda Plast, the manufacturer of
plastic PET preforms for the soft drinks and water industry, at
1.5x cost.
Co-investment in insurance company
ATEC, led by Kester Capital, is performing strongly and returned
£0.7 million from the redemption of loan notes.
Capvis IV has exited Visable, the
e-commerce B2B digital platform business to Alibaba International
Digital Commerce returning £0.7 million (2.0x cost, 11%
IRR).
The total of realisations in 2023
was £61.8 million which is approximately half of the amount
realised in 2022 and 62% down on the peak year of 2021.
Looking at last year's exits in more
detail. There were 51 exits in the year. The average multiple of
cost achieved on exit was 3.0x with an average IRR achieved of 22%.
The average holding period was 6.8 years. The average uplift on
exit was 31% with the companies valued on average at 2.4x cost
immediately prior to exit. The average uplift on exit expressed as
a percentage is very much in line with prior years, but the average
exit multiple is lower with the average exit multiple over the last
four years, when there were 196 exits, being 3.6x cost.
There are some subtle differences in
the type of exits with 60% of exits in 2023 being to other private
equity sponsors and 40% to trade buyers. This is a slightly higher
amount of private equity sponsor exits than the average of the last
four years when it was typically below 60%. There were no exits by
IPO in 2023. Of the exits to other PE houses, nearly a quarter of
the value returned (22%) was from so-called continuation vehicles
where the lead manager continues to lead the deal within a fresh
fund or vehicle with some continuing and some new investors.
Continuation vehicles accounted for 13% of all value returned in
2023 having accounted for zero in 2022.
Whilst these statistics indicate
that exits are numerous and at good values, the reduced overall
volume and the appearance of continuation vehicles implies that
they are harder to achieve. This is entirely consistent with our
experience in the market.
Valuation Changes
There have been many valuation
movements during the year in both directions with a modest net
positive trend. This is very much in line with the feeling
expressed by our investment partners about the business environment
- i.e. one of modest but definite improvement.
The large movements are provided by
our co-investment portfolio which now accounts for 44.6% of the
portfolio.
The largest positive movement this
year was the £9.2 million uplift in the Kester led pet shop chain
Jollyes which, after the year end, agreed a sale to TDR Capital.
The proceeds of the exit are expected to be received imminently and
amount to c.£18.9 million. This is an excellent outcome and
depending on the timing of the proceeds, represents c.3.9x cost and
a net IRR of c.29%. EBITDA has doubled since the company was
acquired in 2018 with the number of its large format pet retail
stores growing from 60 at the time of acquisition to over
100.
The niche insurance company ATEC,
managed by Kester, was the second largest write-up in the year, a
£2.8 million uplift due to strong new business volumes coupled with
robust renewal rates across all product lines.
There was another large uplift in
the consumer sector with clothing company Weird Fish, uplifted by
£2.1 million. The company had a strong finish to the year. They
recently appointed a new CEO with substantial experience in this
industry and an ambitious growth plan is being
implemented.
Other notable uplifts this year are
largely from the co-investment portfolio and cover both
long-established holdings and more recently made investments.
Cyberhawk, the unmanned aerial vehicle (drone) inspection and
software company, is up by £2.8 million. Cardo, the social housing
refurbishment company, is up by £2.2 million. Cyclomedia, the
geospatial data company, is up by £1.7 million. Contained Air
Solutions, the microbiological safety cabinets manufacturer, has
agreed to two complementary acquisitions and experienced stronger
trading in recent months resulting in an uplift of £1.4
million.
Amongst the funds portfolio there
have been notable uplifts from Magnesium Capital I (+£2.7 million
due to very strong trading in the initial three companies), August
Equity V (+£2.5 million), August Equity IV (+£2.4 million) and
Graycliff IV (+£2.4 million due to the excellent trading of EMC,
the manufacturer of electrical equipment which was sold shortly
after year end).
The downgrades were also dominated
by the co-investment portfolio. The largest write-down was from
Ambio, the producer of active pharmaceutical ingredient for
peptide-based pharmaceuticals, which has been written down by £4.7
million over the year due to a sharp reduction reflecting recent
poor performance partially resulting from a serious fire.
Bulgaria-based electric bike company, Leader96, is down by £4.2
million, reflecting weak trading, which is affecting the whole
electric bike sector. Accuvein, the vein visualisation medical
devices company, has been reduced by £3.4 million reflecting a
lower valuation multiple applied by lead manager MVM. Avalon, the
funeral plans co-investment led by Lonsdale, has been written down
by £2.1 million as the market remains depressed with a recovery to
previous levels of demand now considered unlikely. Since regulation
was taken over by the FCA in 2022, the funeral plans sector has
operated amidst significant uncertainty. Amongst the funds
portfolio, Corsair VI is down £0.9 million due to weaker trading in
HungerRush, the point-of-sale software provider to the restaurant
industry. In Europe, DBAG VI is down by £0.5 million, impacted by a
fire at Siblitz and a serious patent related fine at
Polytech.
As the above commentary proves there
are considerable risks involved in private equity investment but
there are also clear benefits of maintaining a well-diversified
portfolio which tends to cushion the inevitable shocks.
Financing
The principal development relating
to the Company's financing is that the borrowing facility, which
was due to expire on 24 June 2024, has been renewed and expanded
giving valuable additional headroom and increasing the borrowing
capacity to reflect the increase in the asset base since the
facility was agreed nearly five years ago. The term loan element of
the facility has been increased from €25 million to €60 million and
the revolving credit facility remains at £95 million. This gives an
increase of around a quarter in the borrowing capacity. The term
loan is provided by RBSI and the revolving credit facility is split
£55 million from RBSI and £40 million from State Street. Although
the margins are slightly higher, we have negotiated an improvement
in the covenants. The new arrangements will last until February
2027 - i.e. three years. As part of the agreement there is the
option for us to ask for an extra year's extension to the facility.
We also have the right to ask for an extension in the RCF by up to
£30 million. Neither of these options are guaranteed but as they
are built into the documentation, they should be straightforward to
action should the banks agree in the future.
At the end of 2023 the net debt of
the Company was £87.2 million which was comfortably within the
limits of the borrowing capacity and represented gearing of 14.6%.
At the time of writing on 15 March 2024, net debt is £99.2 million,
or c.16.6% gearing. This is at the upper end of the normal range -
we have rarely exceeded 20%. Following the receipt of the Jollyes
proceeds, it should reduce to around £80 million or c.13.4%
gearing.
The increase in debt over recent
months is a consequence of a significant slowdown in realisations
whilst continuing with an active programme of new investments. The
renewal and expansion of the borrowing arrangements proceeded
smoothly and is now in place allowing the Company and its
shareholders to be fully invested and to continue to benefit from
gearing, one of the key advantages of the investment trust
structure.
25
Year Anniversary
Having been established on 22 March
1999, the Company has recently celebrated its 25th anniversary.
Over the life of the Company, it has delivered to Shareholders an
excellent return.
An investor investing £100 at the
inception of the Company and re-investing dividends, would now have
£978. This is a share price total return of 878% or 9.6% per annum.
The NAV total return over the same period is 1,158% with an
annualised return of 10.7%. The gains accumulated since the start
of the Company equate to 11.6x the original investment.
By comparison the stock market, as
represented by the FTSE All Share index, has provided a total
return of 244% with an annualised return of 5.1%. A total
gain of approximately 2.4x an investment made in March
1999.
These statistics demonstrate the
long-term benefits of investing in a well-diversified private
equity portfolio.
Conclusion
2023 has been a year of adjustment
where the natural progress of the portfolio has been tempered by
pressures across the portfolio arising from higher interest rates
and the return of high inflation. These factors have created
varying degrees of pressure for portfolio companies whose
managements guided and supported by their private equity partners
have generally coped well. Most of the investee companies have long
term growth characteristics which underpin their individual
investment theses which remain largely intact.
Following three very strong years of
gains considerably aided by a large flow of exits, 2023 has been
characterised, unsurprisingly, by lower volumes of exits. Exits
require the buyers to have adequate risk equity, debt and
confidence and an incentive to deal promptly. Whilst there is no
shortage of equity available, debt has been harder to come by and
is much higher in price. Business and investor confidence has been
more subdued, especially from around mid-year - as we have seen at
many times during the Company's 25-year history, caution tends to
slowdown deal doing. The combination of these factors has
manifested themselves as a reduction in deal activity with exits
proving harder to achieve, pricing being moderated and delays
pushing out exits or indeed cancelling them.
Outlook
In recent months there appears to
have been some signs of improvement with many of our investment
partners and the underlying companies expressing confidence about
the year ahead. Our own pipeline of funds and co-investments
dealflow remains very robust with no shortage of attractive
opportunities to invest shareholders' capital. These factors all
bode well as the Company celebrates 25 years of delivering strongly
for shareholders and embarks on its next quarter
century.
Hamish Mair
Investment Manager
CT Investment Business
Limited
Portfolio Summary
Portfolio Distribution at 31
December 2023
|
% of
Total
31
December 2023
|
% of
Total
31
December 2022
|
Buyout Funds - Pan
European*
|
10.5
|
11.1
|
Buyout Funds - UK
|
16.2
|
15.4
|
Buyout Funds - Continental
Europe†
|
18.2
|
20.1
|
Secondary Funds
|
0.1
|
0.1
|
Private Equity Funds -
USA
|
5.0
|
4.3
|
Private Equity Funds -
Global
|
1.7
|
1.2
|
Venture Capital Funds
|
3.7
|
3.7
|
Direct - Quoted
|
-
|
1.1
|
Direct
Investments/Co-investments
|
44.6
|
43.0
|
|
100.0
|
100.0
|
* Europe including the
UK.
† Europe excluding the
UK.
|
|
|
|
|
|
Ten
Largest Holdings
As
at 31 December 2023
|
Total
Valuation £'000
|
% of Total Portfolio
|
Jollyes
|
18,912
|
3.1
|
Sigma
|
15,750
|
2.6
|
Inflexion Strategic
Partners
|
15,052
|
2.5
|
Coretrax
|
13,915
|
2.3
|
Aliante Equity 3
|
11,528
|
1.9
|
TWMA
|
11,120
|
1.8
|
Bencis V
|
10,752
|
1.8
|
ATEC (CETA)
|
10,543
|
1.7
|
August Equity Partners V
|
10,408
|
1.7
|
San Siro
|
10,368
|
1.7
|
128,348
|
21.1
|
Portfolio Holdings
|
Investment
|
Geographic Focus
|
Total
Valuation
£'000
|
% of Total
Portfolio
|
|
Buyout Funds - Pan European
|
|
|
|
|
F&C European Capital
Partners
|
Europe
|
9,085
|
1.5
|
|
Stirling Square Capital
II
|
Europe
|
9,015
|
1.5
|
|
Apposite Healthcare II
|
Europe
|
8,577
|
1.4
|
|
Apposite Healthcare III
|
Europe
|
7,830
|
1.3
|
|
Magnesium Capital 1
|
Europe
|
5,469
|
0.9
|
|
MED II
|
Western Europe
|
4,272
|
0.7
|
|
Agilitas 2015 Fund
|
Northern Europe
|
3,910
|
0.7
|
|
Astorg VI
|
Western Europe
|
3,007
|
0.5
|
|
Volpi III
|
Northern Europe
|
2,641
|
0.4
|
|
TDR Capital II
|
Western Europe
|
1,458
|
0.2
|
|
Summa III
|
Northern Europe
|
1,383
|
0.2
|
|
Verdane XI
|
Northern Europe
|
1,243
|
0.2
|
|
TDR II Annex Fund
|
Western Europe
|
1,240
|
0.2
|
|
Agilitas 2020 Fund
|
Europe
|
1,151
|
0.2
|
|
ArchiMed MED III
|
Global
|
1,075
|
0.2
|
|
Med Platform II
|
Global
|
881
|
0.2
|
|
KKA II
|
Europe
|
750
|
0.1
|
|
Silverfleet European Dev
Fund
|
Europe
|
627
|
0.1
|
|
Verdane Edda III
|
Northern Europe
|
67
|
-
|
|
Volpi Capital
|
Northern Europe
|
46
|
-
|
|
Wisequity VI
|
Italy
|
42
|
-
|
|
Inflexion Partnership Fund
III
|
Europe
|
(48)
|
-
|
|
Total Buyout Funds - Pan
European
|
|
63,721
|
10.5
|
|
Buyout Funds - UK
|
|
|
|
|
Inflexion Strategic
Partners
|
United Kingdom
|
15,052
|
2.5
|
|
August Equity Partners V
|
United Kingdom
|
10,408
|
1.7
|
|
August Equity Partners IV
|
United Kingdom
|
7,862
|
1.3
|
|
Inflexion Supplemental V
|
United Kingdom
|
7,012
|
1.2
|
|
Axiom 1
|
United Kingdom
|
6,580
|
1.1
|
|
Apiary Capital Partners I
|
United Kingdom
|
6,203
|
1.0
|
|
Inflexion Buyout Fund V
|
United Kingdom
|
5,768
|
0.9
|
|
Kester Capital II
|
United Kingdom
|
4,298
|
0.7
|
|
Piper Private Equity VI
|
United Kingdom
|
3,919
|
0.6
|
|
Inflexion Enterprise Fund
IV
|
United Kingdom
|
3,413
|
0.6
|
|
Inflexion Partnership Capital
II
|
United Kingdom
|
3,347
|
0.6
|
|
FPE Fund II
|
United Kingdom
|
3,153
|
0.5
|
|
Inflexion Buyout Fund IV
|
United Kingdom
|
3,009
|
0.5
|
|
FPE Fund III
|
United Kingdom
|
2,659
|
0.4
|
|
Inflexion Enterprise Fund
V
|
United Kingdom
|
2,400
|
0.4
|
|
Inflexion Buyout Fund VI
|
United Kingdom
|
2,359
|
0.4
|
|
RJD Private Equity Fund
III
|
United Kingdom
|
1,937
|
0.3
|
|
Piper Private Equity VII
|
United Kingdom
|
1,875
|
0.3
|
|
Inflexion Supplemental IV
|
United Kingdom
|
1,462
|
0.2
|
|
GCP Europe II
|
United Kingdom
|
1,260
|
0.2
|
|
Horizon Capital 2013
|
United Kingdom
|
1,067
|
0.2
|
|
Inflexion Partnership Capital
I
|
United Kingdom
|
1,063
|
0.2
|
|
Primary Capital IV
|
United Kingdom
|
1,042
|
0.2
|
|
Kester Capital III
|
United Kingdom
|
560
|
0.1
|
|
Piper Private Equity V
|
United Kingdom
|
320
|
0.1
|
|
Inflexion 2010 Fund
|
United Kingdom
|
73
|
-
|
|
Inflexion 2012 Co-Invest
Fund
|
United Kingdom
|
70
|
-
|
|
Dunedin Buyout Fund II
|
United Kingdom
|
12
|
-
|
|
Total Buyout Funds - UK
|
|
98,183
|
16.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment
|
Geographic Focus
|
Total
Valuation
£'000
|
% of Total
Portfolio
|
|
Buyout Funds - Continental Europe
|
|
|
|
|
Aliante Equity 3
|
Italy
|
11,528
|
1.9
|
|
Bencis V
|
Benelux
|
10,752
|
1.8
|
|
DBAG VII
|
DACH
|
5,549
|
0.9
|
|
Capvis III CV
|
DACH
|
5,372
|
0.9
|
|
Vaaka III
|
Finland
|
5,308
|
0.9
|
|
Avallon MBO Fund III
|
Poland
|
5,273
|
0.9
|
|
Summa II
|
Nordic
|
4,965
|
0.8
|
|
Chequers Capital XVII
|
France
|
4,743
|
0.8
|
|
DBAG VIII
|
DACH
|
4,681
|
0.8
|
|
Montefiore IV
|
France
|
4,529
|
0.8
|
|
Montefiore V
|
France
|
4,151
|
0.7
|
|
Verdane Edda
|
Nordic
|
3,968
|
0.7
|
|
Procuritas VI
|
Nordic
|
3,921
|
0.6
|
|
Italian Portfolio
|
Italy
|
3,415
|
0.6
|
|
ARX CEE IV
|
Eastern Europe
|
3,304
|
0.5
|
|
Corpfin V
|
Spain
|
2,795
|
0.5
|
|
Procuritas Capital IV
|
Nordic
|
2,783
|
0.5
|
|
Corpfin Capital Fund IV
|
Spain
|
2,772
|
0.5
|
|
Summa I
|
Nordic
|
2,480
|
0.4
|
|
NEM Imprese III
|
Italy
|
2,398
|
0.4
|
|
Procuritas VII
|
Nordic
|
2,096
|
0.3
|
|
Capvis IV
|
DACH
|
2,057
|
0.3
|
|
Aurica IV
|
Spain
|
1,400
|
0.2
|
|
Vaaka II
|
Finland
|
1,383
|
0.2
|
|
Portobello Fund III
|
Spain
|
1,287
|
0.2
|
|
Vaaka IV
|
Finland
|
1,250
|
0.2
|
|
Avallon MBO Fund II
|
Poland
|
1,139
|
0.2
|
|
DBAG VIIB
|
DACH
|
1,019
|
0.2
|
|
DBAG Fund VI
|
DACH
|
842
|
0.1
|
|
Chequers Capital XVI
|
France
|
777
|
0.1
|
|
DBAG VIIIB
|
DACH
|
721
|
0.1
|
|
PineBridge New Europe II
|
Eastern Europe
|
470
|
0.1
|
|
Ciclad 5
|
France
|
345
|
0.1
|
|
Procuritas Capital V
|
Nordic
|
209
|
-
|
|
Montefiore Expansion
|
France
|
141
|
-
|
|
Gilde Buyout Fund III
|
Benelux
|
93
|
-
|
|
N+1 Private Equity Fund
II
|
Iberia
|
91
|
-
|
|
Capvis III
|
DACH
|
51
|
-
|
|
DBAG Fund V
|
DACH
|
5
|
-
|
|
Total Buyout Funds - Continental
Europe
|
|
110,063
|
18.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment
|
Geographic Focus
|
Total
Valuation
£'000
|
% of Total
Portfolio
|
|
|
|
|
|
|
|
|
|
|
Private Equity Funds - USA
Blue Point Capital IV
|
North America
|
7,729
|
1.3
|
Graycliff IV
|
North America
|
5,094
|
0.9
|
Graycliff III
|
United States
|
3,108
|
0.5
|
Camden Partners IV
|
United States
|
3,107
|
0.5
|
Stellex Capital Partners
|
North America
|
2,835
|
0.5
|
Blue Point Capital III
|
North America
|
2,562
|
0.4
|
Level 5 Fund II
|
United States
|
2,039
|
0.4
|
Purpose Brands (Level 5)
|
United States
|
1,981
|
0.3
|
MidOcean VI
|
United States
|
1,357
|
0.2
|
Blue Point Capital II
|
North America
|
149
|
-
|
HealthpointCapital Partners
III
|
United States
|
52
|
-
|
Total Private Equity Funds -
USA
|
|
30,013
|
5.0
|
|
|
|
|
|
|
|
|
Private Equity Funds - Global
|
|
|
|
Corsair VI
|
Global
|
5,911
|
1.0
|
Hg Saturn 3
|
Global
|
2,549
|
0.4
|
PineBridge GEM II
|
Global
|
828
|
0.2
|
F&C Climate Opportunities
Partners
|
Global
|
720
|
0.1
|
AIF Capital Asia III
|
Asia
|
91
|
-
|
PineBridge Latin America
II
|
South America
|
56
|
-
|
Warburg Pincus IX
|
Global
|
9
|
-
|
Hg Mercury 4
|
Global
|
(36)
|
-
|
Total Private Equity Funds -
Global
|
|
10,128
|
1.7
|
Venture Capital Funds
|
|
|
|
SEP V
|
United Kingdom
|
9,322
|
1.5
|
MVM V
|
Global
|
4,375
|
0.7
|
Kurma Biofund II
|
Europe
|
3,548
|
0.6
|
Northern Gritstone
|
United Kingdom
|
1,500
|
0.3
|
SEP VI
|
Europe
|
1,221
|
0.2
|
SEP IV
|
United Kingdom
|
1,201
|
0.2
|
Pentech Fund II
|
United Kingdom
|
436
|
0.1
|
SEP II
|
United Kingdom
|
273
|
0.1
|
Life Sciences Partners III
|
Western Europe
|
247
|
-
|
MVM VI
|
Global
|
222
|
-
|
Environmental Technologies
Fund
|
Europe
|
56
|
-
|
SEP III
|
United Kingdom
|
36
|
-
|
Total Venture Capital
Funds
|
|
22,437
|
3.7
|
Secondary Funds
|
|
|
|
The Aurora Fund
|
Europe
|
635
|
0.1
|
Total Secondary Funds
|
|
635
|
0.1
|
|
|
|
|
Investment
|
Geographic Focus
|
Total
Valuation
£'000
|
% of Total
Portfolio
|
Direct Investments/Co-investments
|
|
|
|
Jollyes
|
United Kingdom
|
18,912
|
3.1
|
Sigma
|
United States
|
15,750
|
2.6
|
Coretrax
|
United Kingdom
|
13,915
|
2.3
|
TWMA
|
United Kingdom
|
11,120
|
1.8
|
ATEC (CETA)
|
United Kingdom
|
10,543
|
1.7
|
San Siro
|
Italy
|
10,368
|
1.7
|
Weird Fish
|
United Kingdom
|
9,670
|
1.6
|
Aurora Payment Solutions
|
United States
|
9,435
|
1.6
|
Cyclomedia
|
Netherlands
|
8,994
|
1.5
|
Amethyst Radiotherapy
|
Europe
|
8,142
|
1.3
|
Cyberhawk
|
United Kingdom
|
7,826
|
1.3
|
Utimaco
|
DACH
|
7,192
|
1.2
|
Velos IoT (JT IoT)
|
United Kingdom
|
6,723
|
1.1
|
Rosa Mexicano
|
United States
|
6,473
|
1.1
|
Prollenium
|
North America
|
6,467
|
1.1
|
Asbury Carbons
|
North America
|
6,276
|
1.0
|
Swanton
|
United Kingdom
|
6,273
|
1.0
|
Orbis
|
United Kingdom
|
5,731
|
1.0
|
Family First
|
United Kingdom
|
5,451
|
0.9
|
Contained Air Solutions
|
United Kingdom
|
5,359
|
0.9
|
Cybit (Perfect Image)
|
United Kingdom
|
4,983
|
0.8
|
CARDO Group (Sigma II)
|
United Kingdom
|
4,920
|
0.8
|
123Dentist
|
Canada
|
4,886
|
0.8
|
StarTraq
|
United Kingdom
|
4,858
|
0.8
|
AccuVein
|
United States
|
4,780
|
0.8
|
Braincube
|
France
|
4,592
|
0.8
|
Dotmatics
|
United Kingdom
|
4,350
|
0.7
|
1Med
|
Switzerland
|
4,338
|
0.7
|
Habitus
|
Denmark
|
4,271
|
0.7
|
Omlet
|
United Kingdom
|
4,019
|
0.7
|
LeadVenture
|
United States
|
3,787
|
0.6
|
Agilico (DMC Canotec)
|
United Kingdom
|
3,740
|
0.6
|
Walkers Transport
|
United Kingdom
|
3,645
|
0.6
|
Educa Edtech
|
Spain
|
3,643
|
0.6
|
Alessa (Tier1 CRM)
|
Canada
|
3,388
|
0.6
|
Leader96
|
Bulgaria
|
3,079
|
0.5
|
PathFactory
|
Canada
|
3,050
|
0.5
|
Vero Biotech
|
United States
|
2,699
|
0.4
|
Collingwood Insurance
Group
|
United Kingdom
|
2,671
|
0.4
|
MedSpa Partners
|
Canada
|
2,253
|
0.4
|
Neurolens
|
United States
|
2,208
|
0.4
|
GT Medical
|
United States
|
1,878
|
0.3
|
OneTouch
|
United Kingdom
|
1,863
|
0.3
|
Rephine
|
United Kingdom
|
1,519
|
0.3
|
Ambio Holdings
|
United States
|
1,480
|
0.2
|
Bomaki
|
Italy
|
1,242
|
0.2
|
Avalon
|
United Kingdom
|
1,234
|
0.2
|
TDR Algeco/Scotsman
|
Europe
|
339
|
0.1
|
Babington
|
United Kingdom
|
88
|
-
|
Total Direct -
Investments/Co-investments
|
|
270,423
|
44.6
|
Total Portfolio
|
|
605,603
|
100.0
|
CT Private Equity Trust
PLC
Statement of Comprehensive
Income for the
year ended 31 December
2023
|
(Unaudited)
|
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Income
|
|
|
|
Gains on investments held at fair
value
|
-
|
25,226
|
25,226
|
Exchange gains
|
-
|
863
|
863
|
Investment income
|
2,703
|
-
|
2,703
|
Other income
|
689
|
-
|
689
|
Total income
|
3,392
|
26,089
|
29,481
|
|
|
|
|
Expenditure
|
|
|
|
Investment management fee - basic
fee
|
(474)
|
(4,263)
|
(4,737)
|
Investment management fee -
performance fee
|
-
|
(4,767)
|
(4,767)
|
Other expenses
|
(1,064)
|
-
|
(1,064)
|
Total expenditure
|
(1,538)
|
(9,030)
|
(10,568)
|
|
|
|
|
Profit before finance costs and taxation
|
1,854
|
17,059
|
18,913
|
|
|
|
|
Finance costs
|
(513)
|
(4,616)
|
(5,129)
|
|
|
|
|
Profit before taxation
|
1,341
|
12,443
|
13,784
|
|
|
|
|
Taxation
|
-
|
-
|
-
|
|
|
|
|
Profit for year/total comprehensive income
|
1,341
|
12,443
|
13,784
|
|
|
|
|
Return per Ordinary Share
|
1.84p
|
17.08p
|
18.92p
|
CT
Private Equity Trust PLC
Statement of Comprehensive
Income for the
year ended 31 December
2022
|
(Audited)
|
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Income
|
|
|
|
Gains on investments held at fair
value
|
-
|
77,330
|
77,330
|
Exchange losses
|
-
|
(2,083)
|
(2,083)
|
Investment income
|
4,550
|
-
|
4,550
|
Other income
|
186
|
-
|
186
|
Total income
|
4,736
|
75,247
|
79,983
|
|
|
|
|
Expenditure
|
|
|
|
Investment management fee - basic
fee
|
(464)
|
(4,172)
|
(4,636)
|
Investment management fee -
performance fee
|
-
|
(5,402)
|
(5,402)
|
Other expenses
|
(1,077)
|
-
|
(1,077)
|
Total expenditure
|
(1,541)
|
(9,574)
|
(11,115)
|
|
|
|
|
Profit before finance costs and taxation
|
3,195
|
65,673
|
68,868
|
|
|
|
|
Finance costs
|
(254)
|
(2,294)
|
(2,548)
|
|
|
|
|
Profit before taxation
|
2,941
|
63,379
|
66,320
|
|
|
|
|
Taxation
|
-
|
-
|
-
|
|
|
|
|
Profit for year/total comprehensive income
|
2,941
|
63,379
|
66,320
|
|
|
|
|
Return per Ordinary Share
|
4.01p
|
86.42p
|
90.43p
|
CT
Private Equity Trust PLC
Balance Sheet
|
As at 31 December 2023
(Unaudited)
|
As at 31 December 2022
(Audited)
|
|
£'000
|
£'000
|
Non-current assets
|
|
|
Investments at fair value through
profit or loss
|
605,603
|
528,557
|
|
605,603
|
528,557
|
Current assets
|
|
|
Other receivables
|
841
|
389
|
Cash and cash equivalents
|
9,879
|
34,460
|
|
10,720
|
34,849
|
Current liabilities
|
|
|
Other payables
Interest-bearing bank loan
|
(8,121)
(97,109)
|
(7,411)
(16,618)
|
|
(105,230)
|
(24,029)
|
Net
current (liabilities)/assets
|
(94,510)
|
10,820
|
Total assets less current liabilities
|
511,093
|
539,377
|
|
|
|
Non-current liabilities
|
|
|
Interest-bearing bank loan
|
-
|
(21,702)
|
Net
assets
|
511,093
|
517,675
|
|
|
|
Equity
|
|
|
Called-up ordinary share
capital
|
739
|
739
|
Share premium account
|
2,527
|
2,527
|
Special distributable capital
reserve
|
9,597
|
10,026
|
Special distributable revenue
reserve
|
31,403
|
31,403
|
Capital redemption reserve
|
1,335
|
1,335
|
Capital reserve
|
465,492
|
471,645
|
Shareholders' funds
|
511,093
|
517,675
|
|
|
|
Net
asset value per Ordinary Share
|
702.50p
|
710.65p
|
CT
Private Equity Trust PLC
Statement of Changes in
Equity
|
Share Capital
|
Share
Premium Account
|
Special Distributable Capital
Reserve
|
Special Distributable Revenue
Reserve
|
Capital Redemption
Reserve
|
Capital Reserve
|
Revenue Reserve
|
Total
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
For the year ended 31 December 2023
(unaudited)
|
|
|
|
|
|
|
Net assets at 1 January
2023
|
739
|
2,527
|
10,026
|
31,403
|
1,335
|
471,645
|
-
|
517,675
|
Buyback of ordinary
shares
|
-
|
-
|
(429)
|
-
|
-
|
-
|
-
|
(429)
|
Profit for the year/total
comprehensive income
|
-
|
-
|
-
|
-
|
-
|
12,443
|
1,341
|
13,784
|
Dividends paid
|
-
|
-
|
-
|
-
|
-
|
(18,596)
|
(1,341)
|
(19,937)
|
|
|
|
|
|
|
|
|
|
Net assets at 31 December
2023
|
739
|
2,527
|
9,597
|
31,403
|
1,335
|
465,492
|
-
|
511,093
|
|
|
|
|
|
|
|
|
|
For the year ended 31 December 2022
(audited)
|
|
|
|
|
|
|
Net assets at 1 January
2022
|
739
|
2,527
|
15,040
|
31,403
|
1,335
|
422,403
|
-
|
473,447
|
Buyback of ordinary
shares
|
-
|
-
|
(5,014)
|
-
|
-
|
-
|
-
|
(5,014)
|
Profit for the year/total
comprehensive income
|
-
|
-
|
-
|
-
|
-
|
63,379
|
2,941
|
66,320
|
Dividends paid
|
-
|
-
|
-
|
-
|
-
|
(14,137)
|
(2,941)
|
(17,078)
|
|
|
|
|
|
|
|
|
|
Net assets at 31 December
2022
|
739
|
2,527
|
10,026
|
31,403
|
1,335
|
471,645
|
-
|
517,675
|
|
|
|
|
|
|
|
|
|
CT
Private Equity Trust PLC
Statement of Cash Flows
|
Year ended
31 December
2023
(Unaudited)
|
Year ended
31 December
2022
(Audited)
|
|
|
|
|
£000
|
£000
|
Operating activities
|
|
|
Profit before taxation
|
13,784
|
66,320
|
Adjustments for:
Gains on disposals of
investments
|
(26,349)
|
(62,951)
|
(Losses)/gains on account of fair
value movement
|
1,123
|
(14,379)
|
Exchange differences
|
(863)
|
2,083
|
Interest Income
|
(689)
|
(186)
|
Interest received
|
668
|
186
|
Finance costs
|
5,129
|
2,548
|
Increase in other
receivables
|
(8)
|
(2)
|
(Decrease)/increase in other
payables
|
(497)
|
358
|
Net
cash outflow from operating activities
|
(7,702)
|
(6,023)
|
|
|
|
Investing activities
|
|
|
Purchases of investments
|
(110,784)
|
(88,593)
|
Sales of investments
|
58,964
|
120,413
|
Net
cash (outflow)/inflow from investing activities
|
(51,820)
|
31,820
|
|
|
|
Financing activities
|
|
|
Drawdown of bank loans
|
59,023
|
-
|
Arrangement costs of loan facility
|
(27)
|
(28)
|
Interest paid
|
(3,995)
|
(1,919)
|
Equity dividends paid
|
(19,937)
|
(17,078)
|
Buyback of ordinary
shares
|
(429)
|
(5,014)
|
Net
cash inflow/(outflow) from financing activities
|
34,635
|
(24,039)
|
Net (decrease)/increase in cash and
cash equivalents
|
(24,887)
|
1,758
|
Currency gains
|
306
|
-
|
Net
(decrease)/increase in cash and cash equivalents
|
(24,581)
|
1,758
|
Opening cash and cash
equivalents
|
34,460
|
32,702
|
Closing cash and cash equivalents
|
9,879
|
34,460
|
|
|
|
|
Notes (unaudited)
1.
The unaudited financial results, which were approved by the Board
on 2 April 2024, have been prepared in accordance with UK adopted
international accounting standards. Where presentation guidance set
out in the Statement of Recommended Practice "Financial Statements
of Investment Trust Companies and Venture Capital Trusts" ('SORP')
issued by the Association of Investment Companies is consistent
with the requirements of international accounting standards, the
Directors have sought to prepare the financial statements on a
basis compliant with the recommendations of the SORP. The
Directors have assessed Going Concern and consider it the
appropriate basis for the figures presented in the
announcement.
The accounting policies adopted are
consistent with those of the previous financial year.
Standards issued but not yet
effective
There are no standards or amendments
to standards not yet effective that are relevant to the Company and
should be disclosed.
2.
Returns per Ordinary Share are based on the following weighted
average number of shares in issue during the year: 72,838,637
(2022: 73,342,303)
The net asset value per Ordinary
Share is based on the following number of shares in issue at the
year-end: 72,752,938 (2022: 72,844,938)
During the year ended 31 December
2023, the Company issued nil Ordinary Shares. During the
previous year ended 31 December 2022, the Company issued nil
Ordinary Shares. During the year ended 31 December 2023, the
Company bought back 92,000 Ordinary Shares to be held in treasury.
During the previous year ended 31 December 2022, the Company bought
back 1,096,491 Ordinary Shares to be held in treasury.
3.
The Board has proposed an interim dividend of 7.01 pence per
Ordinary Share, payable on 30 April 2024 to those Shareholders on
the register on 12 April 2024 with an ex-dividend date of 11 April
2024.
4.
This results announcement is based on the Company's unaudited
financial statements for the year ended 31 December 2023 which have
been prepared in accordance with UK adopted international
accounting standards.
5.
This announcement is not the Company's statutory accounts.
The full audited accounts for the year ended 31 December 2022,
which were unqualified and had no emphasis of matters, have been
lodged with the Registrar of Companies. The statutory
accounts for the year to 31 December 2023 (on which the audit
report has not yet been signed) will be delivered to the Registrar
of Companies following the Company's Annual General Meeting which
will be held at Cannon Place, 78 Cannon Street Street, London, EC4N
6AG on 29 May 2024 at 12 noon.
6.
The Annual Report and Accounts for the year will be sent to
Shareholders and will be available for inspection at the Company's
registered office, Quartermile 4, 7a Nightingale Way, Edinburgh,
EH3 9EG and the Company's website www.ctprivateequitytrust.com.
The Company intends to issue a subsequent annual financial report
announcement.
For more information, please
contact:
Appendix:
Alternative Performance Measures
The Company uses the following
Alternative Performance Measures ('APMs'):
Discount (or premium) - If the
share price of an Investment Trust is less than its Net Asset Value
per share, the shares are trading at a discount. If the share
price is greater than the Net Asset Value per share, the shares are
trading at a premium.
|
|
31
December 2023
|
31
December 2022
|
Net Asset Value per share
(pence)
|
(a)
|
702.50
|
710.65
|
Share price per share
(pence)
|
(b)
|
468.00
|
423.00
|
Discount (c=(b-a)/a)
|
(c)
|
33.4%
|
40.5%
|
Dividend Yield - The dividends
declared for the year divided by the share price at the year
end.
Gearing - This is the ratio of
the borrowings less cash of the Company to its total assets less
current liabilities (excluding borrowings and cash).
Borrowings may include: preference shares; debentures; overdrafts
and short and long-term loans from banks; and derivative
contracts. If the Company has cash assets, these may be
assumed either to net off against borrowings, giving a "net" or
"effective" gearing percentage, or to be used to buy investments,
giving a "gross" or "fully invested" gearing figure. Where
cash assets exceed borrowings, the Company is described as having
"net cash".
|
|
31
December 2023
|
31
December 2022
|
|
|
£'000
|
£'000
|
Borrowings less cash
|
(a)
|
87,230
|
3,860
|
Total assets less current
liabilities (excluding borrowings and cash)
|
(b)
|
598,323
|
521,535
|
Gearing (c=a/b)
|
(c)
|
14.6%
|
0.7%
|
Ongoing Charges - All operating
costs expected to be incurred in future and that are payable by the
Company expressed as a proportion of the average Net Assets of the
Company over the reporting year. The costs of buying and
selling investments are excluded, as are interest costs, taxation,
performance fees, non-recurring costs and the costs of buying back
or issuing Ordinary Shares. Ongoing charges of the Company's
underlying investments are also excluded.
|
Year
to
31
December 2023
|
Year
to
31
December 2022
|
Ongoing charges (£'000)
|
5,801
|
5,713
|
Ongoing charges as a percentage of
average assets:
|
1.1%
|
1.2%
|
Ongoing charges (including
performance fees) (£'000)
|
10,568
|
11,115
|
Ongoing charges (including
performance fees) as a percentage of average net assets:
|
2.1%
|
2.3%
|
Average net assets
(£'000)
|
508,718
|
491,918
|
Total Return - The return to
Shareholders calculated on a per share basis by adding dividends
paid in the period to the increase or decrease in the Share Price
or NAV. The dividends are assumed to have been reinvested in the
form of Ordinary Shares or Net Assets.
|
Year to 31
December 2023
|
Year to 31
December 2022
|
NAV per share at start of year
(pence)
|
710.65
|
640.30
|
NAV per share at end of year
(pence)
|
702.50
|
710.65
|
Change in year
|
-1.1%
|
+11.0%
|
Impact of dividend
reinvestments
|
+3.9%
|
+3.8%
|
Total NAV return for the
year
|
+2.8%
|
+14.8%
|
|
Year to 31
December 2023
|
Year to 31
December 2022
|
Share price per share at start of
year (pence)
|
423.00
|
489.00
|
Share price per share at end of year
(pence)
|
468.00
|
423.00
|
Change in year
|
+10.6%
|
-13.5%
|
Impact of dividend
reinvestments
|
+7.0%
|
+4.6%
|
Total share price return for the
year
|
+17.6%
|
-8.9%
|